Immune checkpoint inhibitors
- 39 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
In a study, six patients (5 women and 1 man) aged 50−81 years were described, who developed de novo myositis during treatment with atezolizumab, pembrolizumab, ipilimumab or nivolumab and ipilimumab. Five of these 6 patients developed additional immune-related adverse events (irAE) comprising myocarditis, myasthenic syndrome, pneumonitis, hypothyroidism, vitiligo, autoimmune haemolytic anaemia or immune thrombocytopenic purpura [dosages and routes not stated; not all times to reaction onsets and outcomes stated]. These 6 patients received immune checkpoint therapies (atezolizumab, pembrolizumab, ipilimumab or nivolumab and ipilimumab) between January 2004 and September 2016 as a treatment of cancer.
Patient 1: A 73-year-old man developed myocarditis and de novo myositis during...
- Shah M, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism 48: 736-740, No. 4, Feb 2019. Available from: URL: https://doi.org/10.1016/j.semarthrit.2018.05.006Google Scholar